Ropes & Gray advised Monte Rosa Therapeutics on the transaction. Monte Rosa Therapeutics (Nasdaq: GLUE) has entered into a global exclusive licensing agreement with Novartis to...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented CAMP4 Therapeutics in the transaction, and Paul Hastings represented the underwriters. CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company, announced...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Genesis Therapeutics on the transaction. Genesis Therapeutics (Nasdaq: GILD) announced it has entered into a strategic collaboration with Gilead Sciences, Inc. to...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Ionis Pharmaceuticals in the deal. Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka)...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Foghorn Therapeutics Inc. on the offering, and Latham & Watkins advised the underwriters. Foghorn Therapeutics Inc. (Nasdaq: FHTX) (“Foghorn”), a clinical-stage biotechnology...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Fulcrum Therapeutics on the transaction. Fulcrum Therapeutics, Inc. (Fulcrum) (Nasdaq: FULC) announced it has entered into a collaboration and license agreement with...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Chiesi Group on the transaction, and Latham & Watkins advised Gossamer Bio. Chiesi Group announced it has entered into a global collaboration...
You must be a Standard 1 Year member to access this content.
Morgan, Lewis & Bockius acted as legal counsel to Eli Lilly, and Ropes & Gray acted as legal counsel to Sigilon. Eli Lilly and Company (NYSE:...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Goldfinch Bio on the deal. Goldfinch Bio announced an exclusive global license agreement with Karuna Therapeutics under which Karuna will have development, manufacturing...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented HUTCHMED on the deal. HUTCHMED (China) Limited and its subsidiary, HUTCHMED Limited announced an exclusive worldwide license agreement with Japan’s largest drugmaker Takeda...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Scipher Medicine on the deal. Precision immunology company Scipher Medicine announced its acquisition of data, analytics and software company CrossBridge to enhance...
You must be a Standard 1 Year member to access this content.
Kirkland & Ellis advised Patient Square Capital, Ropes & Gray advised Radius, Latham & Watkins advised Gurnet Point Capital, Covington & Burling served as OrbiMed’s legal...
You must be a Standard 1 Year member to access this content.
